¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"A form particle"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • charged particle radiation
    ÇÏÀüÀÔÀÚ¹æ»ç¼±
  • defective interfering particle
    °á¼Õ°£¼·ÀÔÀÚ
  • diamagnetic particle
    ¹ÝÀÚ¼ºÀÔÀÚ
  • elementary particle
    ¼Ò¸³ÀÚ
  • ferromagnetic particle
    °­ÀÚ¼ºÀÔÀÚ
  • heredity particle
    À¯ÀüÀÔÀÚ
  • particle
    ÀÔÀÚ
  • particle accelerator
    ÀÔÀÚ°¡¼Ó±â
  • particle attraction
    ÀÔÀÚÀηÂ
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • particle immunoassay
    ÀÔÀڸ鿪ºÐ¼®(¹ý)
  • particle radiation
    ÀÔÀÚ¹æ»ç¼±
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • suspended particle
    ºÎÀ¯ÀÔÀÚ, ÇöŹÀÔÀÚ, ¶áÀÔÀÚ
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ, ¹ÙÀ̸®¿Â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta particle
    º£Å¸ÀÔÀÚ
  • charged particle
    ÇÏÀüÀÔÀÚ, ´ëÀüÀÔÀÚ
  • charged particle equilibrium
    ÇÏÀüÀÔÀÚÆòÇü, Àü±âÀÔÀÚÆòÇü
  • charged particle radiation
    ÇÏÀüÀÔÀÚ¹æ»ç¼±
  • coarse particle
    Á¶¸³ÀÚ, °ÅÄ£ÀÔÀÚ
  • particle count
    ÀÔÀÚ°èÃø
  • defective interfering particle
    °á¼Õ°£¼·ÀÔÀÚ
  • diamagnetic particle
    ¹ÝÀÚ¼ºÀÔÀÚ
  • elementary particle
    »ý¼Ò¸³ÀÚ, ¼Ò¸³ÀÚ
  • ferromagnetic particle
    öÀÚ¼ºÀÔÀÚ
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • heredity particle
    À¯ÀüÀÔÀÚ
  • particle immunoassay
    ÀÔÀڸ鿪ºÐ¼®(¹ý)
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • particle
    ÀÔÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Dane particle
    µ¥ÀÎÀÔÀÚ
  • Dane particle
    µ¥ÀÎÀÔÀÚ (BÇü °£¿°¹ÙÀÌ·¯½ºÀÇ)
  • Dane particle
    µ¥ÀÎÁ¶°¢,µ¥ÀÎÀÎÀÚ
  • PCFIA => particle concentration fluorescence immunoassay
    ÀÔÀÚ³óÃàÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • heavy charged particle
    ÁßÇÏÀüÀÔÀÚ
  • heavy particle
    ÁßÀÔÀÚ(ñìí£í­).
  • heavy particle
    ÁßÀÔÀÚ
  • heredity particle
    À¯ÀüÀÔÀÚ(ë¶îîí£í­).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heavy particle
    ÁßÀÔÀÚ
  • heredity particle
    À¯ÀüÀÔÀÚ(ë¶îîí£í­).
  • lambda particle
    ¶÷´ÙÀÔÀÚ(¡­í£í­).
  • lambda particle
    ¶÷´ÙÀÔÀÚ
  • light particle
    °æÀÔÀÚ(Ë­ËöËö).
  • olfactory particle
    ÈļÒ(ý«áÈ).
  • olfactory particle
    ÈļÒ
  • particle accelerator
    ÀÔÀÚ°¡¼Ó±â
  • particle agglutination
    ÀÔÀÚÀÀÁý
  • particle attraction
    ÀÔÀÚÀηÂ(í£í­ìÚæ³).
  • particle beam therapy
    ÀÔÀÚºöÄ¡·á
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • particle concentration fluorescence immunoassay
    ÀÔÀÚ³óÃàÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • particle count
    ÀÔÀÚ°èÃø
  • particle detector
    ÀÔÀÚ°ËÃâ±â(¡­ËþõóÐï).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • CM-particle
    CM¡¤ÀÔÀÚ(Ø£í­)
  • core particle
    ÇÙ½ÉÀÔÀÚ(ú·ãýØ£í­)
  • Dane particle
    ´ëÀÎ ÀÔÀÚ(Ø£í­)
  • deletion-substitution particle
    °á¼ÕġȯÀÔÀÚ(ÌÀáßöÇüµØ£í­)
  • electron transport particle
    ÀüÀÚ¼ö¼Û ÀÔÀÚ(ï³í­âÃáêØ£í­)
  • elementary particle
    »ý¼Ò¸³ÀÚ(ßæáÈØ£í­)
  • ETS particle
    ETS ÀÔÀÚ (Ø£í­)
  • inner membrane particle
    ³»¸·ÀÔÀÚ(Үدأí­)
  • inside-out particle
    ³»¿ÜÀüµµ ÀÔÀÚ(Ò®èâï´ÓîØ£í­)
  • ionizing particle
    ÀÌ¿ÂÈ­(ûù) ÀÔÀÚ(Ø£í­)
  • kappa particle
    Ä«ÆÄ ÀÔÀÚ(Ø£í­)
  • killer particle
    »ìÀÔÀÚ(߯أí­)
  • messenger ribonucleoprotein particle
    Àü·É(îîÖµ) ¸®º¸ÇÙ»ê(ß«)´Ü¹éÁú ÀÔÀÚ(Ó±ÛÜòõØ£í­)
  • particle diffusion
    ÀÔÀÚÈ®»ê(Ø£í­üªß¤)
  • particle electrophoresis
    ÀÔÀÚ Àü±â¿µµ¿(Ø£í­ï³Ñ¨ç¶ÔÑ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IAP immunosuppressive acidic protein; inosinic acid pyrophosphorylase; Institute of Animal Physiology; i...
IMP idiopathic myeloid proliferation; impression; incomplete male pseudohermaphroditism; individual Medi...
IPP independent practice plan; individual patient profile; inflatable penile prosthesis; inorganic pyrop...
LAI latex particle agglutination inhibition; leukocyte adherence inhibition
LECP low-energy charged particle
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
mRNP messenger ribonucleoprotein particle
PA Particle Agglutination
PCFIA Particle Concentration Fluorescence Immuno Assay
PACIA Particle Counting ImmunoAssay
PIXE Particle Induced X-ray Emission
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • anatomic form
    ÇØºÎÇÐÀû ÇüÅÂ
  • anterior tooth form
    ÀüÄ¡ºÎ Ä¡Çü
  • atrophic form
    À§Ãà ÇüÅÂ
  • auxiliary retention form
    º¸Á¶Àû À¯Áö ÇüÅÂ
  • balanced form
    ±ÕÇüÇü
  • band form
    ´ë»óü, °£»ó, °£»ó ¼¼Æ÷, ´ë»óÇü
  • box-form
    »óÇü ¿Íµ¿ÀÇ
  • chemical form
    È­ÇÐÀû Çü»ó
  • circumscribed form
    ±¹ÇѼº ÇüÅÂ
  • color form sorting test
    »öä ÇüÅ Ã߸®±â °Ë»ç
  • convenience form
    ÆíÀÇ ÇüÅÂ
    ÃæÀü¿¡ ÇÊ¿¬ÀûÀÎ ±âº»ÀûÀÎ ¿Íµ¿ÀÇ ÇüÅ·μ­ ¿Íµ¿Àº ¾ðÁ¦³ª ¸ðµç ÃæÀü Á¶ÀÛ¿¡ À־ ±× Á¶ÀÛÀ» ÆíÇÏ°Ô ÇÒ ¼ö ÀÖ´Â ÀûÀýÇÑ ÇüÅ·Π¿Íµ¿À» Çü¼ºÇÏ´Â °Í.
  • crescent form
    ¹Ý´ÞÇü, ¹Ý¿ùü, ¹Ý¿ùÇü
  • facial form
    ¾È¸ð
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • initial form
    Ãʱâ ÇüÅÂ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
D.I. particle <abbreviation> Defective interfering particle.
(05 Mar 2000)
dressed particle <radiobiology> A particle plus its associated neutralising Debye sphere.
(09 Oct 1997)
intramembranous particle <cell biology> Particles (or complementary pits) seen in freeze fractured membranes. The cleavage plane is through the centre of the bilayer and the particles are usually assumed to represent Integral membrane proteins (or polymers of such proteins).
(18 Nov 1997)
either particle flux density The particle fluence rate, or energy flux density, the energy fluence rate of intensity.
Compare: fluence.
(05 Mar 2000)
elementary particle interactions The interactions of particles responsible for their scattering and transformations (decays and reactions). Because of interactions, an isolated particle may decay into other particles. Two particles passing near each other may transform, perhaps into the same particles but with changed momenta (elastic scattering) or into other particles (inelastic scattering). Interactions fall into three groups: strong, electromagnetic, and weak.
(12 Dec 1998)
trapped-particle instability <radiobiology> Slowly-growing class of instabilities driven by particles which cannot circulate freely in a toroidal system.
See: banana orbit.
(09 Oct 1997)
kappa particle <microbiology> Gram-negative bacterial endosymbiont of Paramoecium spp., (Caedobacter taeniospiralis) that confers the killer trait, infected Paramoecium are resistant to the toxin liberated by infected forms. Killing activity is associated with the induction of defective phage in the endosymbiont, leading to the release of R bodies, coded for by the phage genome and apparently of mis assembled phage coat protein.
(18 Nov 1997)
Zimmermann's elementary particle <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
a-form DNA <molecular biology> One of several forms that can be assumed by a double helix. A-DNA is stable in dehydrated conditions.
This form is less common than the dominant form found under physiological conditions -- beta-DNA. This form is also assumed by DNA-RNA hybrid helices and by regions of double-stranded RNA. It is a right-handed helix and is a more compact form than beta-DNA.
(09 Oct 1997)
boat form The less stable of two conformations assumed by 6-membered cyclic sugars (pyranoses) or cyclohexane derivatives, as opposed to chair form.
See: Haworth conformational formulas of cyclic sugars.
(05 Mar 2000)
cavity preparation form The configuration or shape of a cavity preparation.
(05 Mar 2000)
replicative form An intermediate stage in the replication of either DNA or RNA viral genomes that is usually double stranded, the altered, double-stranded form to which single-stranded coliphage DNA is converted after infection of a susceptible bacterium, formation of the complementary ("minus") strand being mediated by enzymes that were present in the bacterium before entrance of the viral ("plus") strand.
(05 Mar 2000)
resistance form The shape given to a cavity preparation that enables the dental restoration to withstand masticatory forces.
(05 Mar 2000)
retention form The shape of a cavity preparation that prevents displacement of the dental restoration by lateral or tipping forces as well as masticatory forces.
(05 Mar 2000)
chair form The more stable of two conformations assumed by 6-membered cyclic sugars (e.g., the pyranoses) or cyclohexane derivatives, as opposed to boat form.
See: Haworth conformational formulas of cyclic sugars.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clipped form(word)
    (³¹¸»ÀÇ)´ÜÃàÇü
  • combining form
    ¿¬°áÇü(º¹Çվ ¸¸µå´Â ¿ä¼Ò)
  • dress form
    (¾çÀç¿ë)ÀÎü ¸ðÇü
  • form
    ¸ð¾ç;¿ÜÇü;¸ð½À;¸ö¸Å;Çü½Ä;¹æ½Ä;Çü;Çü¼ºµÇ´Ù;»ý±â´Ù;´ëÇüÀ̵ǴÙ;Çü¼ºÇÏ´Ù;Çüü¸¦ ÀÌ·ç´Ù;´Ü·ÃÇÏ´Ù. formable a.
  • form board
    (ÄÜÅ©¸®Æ® °ø»çÀÇ) ÇüƲ
  • form class
    ÇüÅ·ù(ÇüÅÂÀû Ư¡À» °øÀ¯ÇÏ´Â ¾î±º µî)
  • form criticism
    ¾ç½Ä ºñÆòÇÐ
  • form frag
    (À¯Ã¼ ¼ÓÀ» ¿îµ¿ÇÏ´Â ¹°Ã¼ÀÇ) Çü»ó Ç×·Â
  • form genus
    ÇüżÓ
  • form letter
    °°Àº ±ÛÀÇ ÆíÁö(Àμâ,º¹»çµÈ)
  • form master
    ÇÐ±Þ ´ãÀÓ ±³»ç
  • form sheet
    (°æ¸¶ÀÇ) ¿¹»óÁö;(Èĺ¸ÀÚ,°æ±âÀÚ¿¡ °üÇÑ) »ó¼¼ÇÑ ±â·Ï
  • form word
    =FUNCTON WORD
  • free form
    ÀÚÀ¯Çü½Ä
  • inner speech form
    ³»ºÎ ¾ð¾î Çü½Ä
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á